Course: Optimizing Outcomes in Newly Diagnosed Multiple Myeloma: The Role of CD38 Monoclonal Antibodies – A Clinical Commentary Activity
CME Credits: 0.75
Released: 2025-01-17
New data on quadruplet regimens offer more therapeutic options to patients with multiple myeloma. Topics discussed include the role of minimal residual disease, recent clinical trial results (eg, CEPHEUS, PERSEUS, IMROZ, and IsKia), and patient quality of life.
Upon completion of this educational activity, participants should be able to:
View Full Course